Keppra
Epilepsy, Idiopathic Generalized
Mazandaran University of Medical SciencesPhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Epilepsy, Idiopathic Generalized cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valproic Acid Mazandaran University of Medical Sciences | Phase 4 | BB |
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →